Drugs

, Volume 67, Issue 13, pp 1905–1915 | Cite as

Fluticasone Furoate

Intranasal Use in Allergic Rhinitis
Adis Drug Profile

Abstract

  • ▲ Fluticasone furoate nasal spray is a new topical intranasal corticosteroid with enhanced affinity for the glucocorticoid receptor and low systemic exposure, which was recently approved in the US for the treatment of seasonal or perennial allergic rhinitis in adults and in children aged >2 years.

  • ▲ Fluticasone furoate nasal spray employs a novel delivery device with a unique side-actuated design, a short nozzle and a new trigger mechanism designed for ease of use.

  • ▲ In well controlled clinical trials, intranasal fluticasone furoate 110µg once daily for 2 weeks in adults and adolescents with seasonal allergic rhinitis reduced nasal and ocular symptoms, and improved health-related quality of life to a significantly greater extent than placebo.

  • ▲ Similarly, treatment with intranasal fluticasone furoate 110µg once daily for 4–6 weeks in adults and adolescents with perennial allergic rhinitis was superior to placebo in reducing nasal symptoms and with respect to overall response to therapy.

  • ▲ In children aged 6–11 years, fluticasone furoate nasal spray was shown to be effective in reducing the nasal symptoms of seasonal and perennial allergic rhinitis following treatment for 2 and 4 weeks, respectively.

  • ▲ Fluticasone furoate nasal spray was well tolerated in adults, adolescents and children aged 2–11 years, with an overall incidence of adverse events similar to that with placebo.

References

  1. 1.
    van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000 Feb; 55(2): 116–34PubMedCrossRefGoogle Scholar
  2. 2.
    Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998 Nov; 81 (5 Pt 2): 478–518PubMedCrossRefGoogle Scholar
  3. 3.
    Blaiss MS. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004 Dec; 20(12): 1937–52PubMedCrossRefGoogle Scholar
  4. 4.
    Van Hoecke H, Van Cauwenberge P. Critical look at the clinical practice guidelines for allergic rhinitis. Respir Med 2007 Apr; 101(4): 706–14PubMedCrossRefGoogle Scholar
  5. 5.
    Walker S, Khan-Wasti S, Fletcher M, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. Epub 2007 Jun 8Google Scholar
  6. 6.
    Price D, Bond C, Bouchard J, et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J 2006 Feb; 15(1): 58–70PubMedCrossRefGoogle Scholar
  7. 7.
    Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma: ARIA workshop report. World Health Organization. J Allergy Clin Immunol 2001 Nov; 108 (5 Suppl.): S147–S334 (Pocket Guide [online]. Available from URL: http://www.whiar.org [Accessed 2007 Jul 26])PubMedCrossRefGoogle Scholar
  8. 8.
    Berger W, Godfrey JW, Grant AC, et al. Fluticasone furoate (FF) nasal spray: development of a next-generation delivery system for allergic rhinitis [abstract no. 907]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S231CrossRefGoogle Scholar
  9. 9.
    US FDA. Veramyst™ (fluticasone furoate) nasal spray: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/ [Accessed 2007 May 11]
  10. 10.
    Biggadike K, Bledsoe R, Hassell A, et al. Fluticasone furoate (FF): interactions with the glucocorticoid receptor [abstract no. P219]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A91–2. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)Google Scholar
  11. 11.
    Salter M, Biggadike K, Clackers M, et al. GW685698X — enhanced affinity for the glucocorticoid receptor: cellular and in vivo pharmacology [abstract no. 781]. 25th Congress of the European Academy of Allergology and Clinical Immunology; 2006 Jun 10–14; ViennaGoogle Scholar
  12. 12.
    Salter M, Biggadike K, Clackers M, et al. Fluticasone furoate (FF): enhanced cellular and tissue protection with a new selective glucocorticoid agonist [abstract no. P212]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A89. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)CrossRefGoogle Scholar
  13. 13.
    Stuebner P. Effects of the novel intranasal glucocorticosteroid Gw685698 (200 µg once-daily) on seasonal allergic rhinitis (SAR) symptoms induced in the Vienna challenge chamber model (VCC) [abstract no. 1232]. J Allergy Clin Immunol 2006 Feb; 117 (2 Suppl. 1): S319CrossRefGoogle Scholar
  14. 14.
    Tripathy I, Sterling R, Clements D, et al. Lack of effect on hypothalamic-pituitary-adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 meg in children with perennial allergic rhinitis [abstract no. 909]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S232CrossRefGoogle Scholar
  15. 15.
    Patel D, Ratner P, Clements D, et al. Lack of effect on hypothalamic-pituitary-adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 mcg in adolescents and adults with perennial allergic rhinitis [abstract no. 1191]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S305CrossRefGoogle Scholar
  16. 16.
    Gradman J, Caldwell M, Wolthers O. Knemometric assessment of short-term lower-leg growth in children with allergic rhinitis (AR) treated with fluticasone furoate (FF) nasal spray [abstract no. 1187]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S304CrossRefGoogle Scholar
  17. 17.
    Allen A, Down G, Newlands A, et al. Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects [abstract no. P210]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A89. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)CrossRefGoogle Scholar
  18. 18.
    Hughes S, Shardlow P, Rousell V, et al. Disposition and metabolism of a novel enhanced affinity glucocorticoid, [14C]-fluticasone furoate (FF) after oral and intravenous (IV) administration in healthy male subjects [abstract no. P216]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A90–1. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)Google Scholar
  19. 19.
    Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007 Mar–Apr; 28(2): 216–25PubMedCrossRefGoogle Scholar
  20. 20.
    Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007 Jun; 119(6): 1430–7PubMedCrossRefGoogle Scholar
  21. 21.
    Hampel Jr FC, Jacobs R, Martin B, et al. Once-daily fluticasone furoate nasal spray (FF) provides 24-hour symptom relief in subjects with seasonal allergic rhinitis (SAR) caused by mountain cedar pollen [abstract no. 1190]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S304–5. Plus poster presented at the 2007 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology; 2007 Feb 23–27; San Diego (CA)CrossRefGoogle Scholar
  22. 22.
    Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007 Sep; 62(9): 1078–84PubMedCrossRefGoogle Scholar
  23. 23.
    Meltzer EO, Tripathy I, Lee J, et al. Once-daily fluticasone furoate nasal spray (FF) provides 24-hour relief of the nasal symptoms of seasonal allergic rhinitis (SAR) in children ages 2–11 years [abstract no. 1193]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S305CrossRefGoogle Scholar
  24. 24.
    Nathan R, Berger W, Yang W, et al. Once daily fluticasone furoate nasal spray (FFNS), a novel enhanced affinity steroid, provides 24-hour relief for the nasal symptoms of perennial allergic rhinitis (PAR) [abstract no. 254]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S65CrossRefGoogle Scholar
  25. 25.
    Vasar M, Houle P-A, Douglass JA, et al. A novel enhancedaffinity corticosteroid, once daily fluticasone furoate nasal spray (FFNS), provides 24-hour relief for the nasal symptoms of perennial allergic rhinitis (PAR) [abstract no. 626 plus poster]. XXVI Congress of the European Academy of Allergology and Clinical Immunology; 2007 Jun 9–13; GöteborgGoogle Scholar
  26. 26.
    Maspero JF, Rosenblut A, Finn Jr A, et al. Once-daily fluticasone furoate nasal spray (FF) is safe and effective in the long-term treatment of perennial allergic rhinitis (PAR) in children ages 2 to 11 years [abstract no. 1189]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S304. Plus poster presented at the 2007 Annual Meeting of the American Academy of Allergy, Asthma and Immunology; 2007 Feb 23–27; San Diego (CA)CrossRefGoogle Scholar
  27. 27.
    Stanford R, Philpot E, Faris M, et al. Fluticasone furoate nasal spray once-daily improves quality of life in subjects with seasonal allergic rhinitis (SAR) [abstract no. P214]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A90. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)Google Scholar
  28. 28.
    Given J, Toler T, Ellsworth A, et al. Once-daily fluticasone furoate nasal spray (FFNS) 110mcg improves quality of life (QoL) in subjects with seasonal allergic rhinitis (SAR) during the ragweed season [abstract no. 1188]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S304CrossRefGoogle Scholar
  29. 29.
    van Bavel J, Toler T, Ellsworth A, et al. Once-daily fluticasone furoate nasal spray (FFNS) improves quality of life (QoL) in subjects with seasonal allergic rhinitis (SAR) during the mountain cedar pollen season [abstract no. 903]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S230Google Scholar
  30. 30.
    Stanford R, Philpot E, Faris M, et al. Fluticasone furoate nasal spray once-daily improves nocturnal quality of life in subjects with seasonal allergic rhinitis (SAR) [abstract no. P208]. Ann Allergy Asthma Immunol 2007 Jan; 98 (1 Suppl. 1): A88–9. Plus poster presented at the 2006 Annual Meeting of the American College of Allergy, Asthma and Immunology; 2006 Nov 9–15; Philadelphia (PA)Google Scholar
  31. 31.
    Ratner P, Andrews C, van Bavel J, et al. Once-daily fluticasone furoate nasal spray (FF) effectively treats ocular symptoms of seasonal allergic rhinitis (SAR) caused by mountain cedar pollen [abstract no. 908]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl. 1): S231. Plus poster presented at the 2007 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology; 2007 Feb 23–27; San Diego (CA)CrossRefGoogle Scholar
  32. 32.
    Fokkens W, Jogi R, Sidorenko I, et al. Fluticasone furoate nasal spray (FFNS) 110 µg once-daily is effective in seasonal allergic rhinitis (SAR) caused by grass pollen [abstract no. 352 plus poster]. XXVI Congress of the European Academy of Allergology and Clinical Immunology; 2007 Jun 9–13; GöteborgGoogle Scholar
  33. 33.
    Meltzer E, Lee J, Tripathy I, et al. Study to assess the efficacy and safety of two doses of fluticasone furoate nasal spray in children with seasonal allergic rhinitis [abstract no. 343 plus poster]. XXVI Congress of the European Academy of Allergology and Clinical Immunology; 2007 Jun 9–13; GöteborgGoogle Scholar
  34. 34.
    Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007 Sep; 62(9): 1071–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Wolters Kluwer Health ¦ AdisMairangi Bay, North Shore, AucklandNew Zealand
  2. 2.Wolters Kluwer HealthConshohockenUSA

Personalised recommendations